ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Markets

Samsung Biologics under scrutiny again over 2016 IPO

Korea Exchange suspected of loosening regulations to help listing

SEOUL -- Samsung Biologics is once again under scrutiny over its 2016 initial public offering as prosecutors raided the office of the Korea Exchange in Seoul on Friday.

The investigation, which follows an earlier probe into Samsung BioLogic's accounting practices ahead of the listing, is a blow for the Samsung group, which has been hoping to turn biotech into a new pillar of growth.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more